Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide
about
Human CD8 responses to a complete epitope set from preproinsulin: implications for approaches to epitope discovery.Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetopeAutoreactive CD8 T cells associated with beta cell destruction in type 1 diabetesTreg vaccination with a strong-agonistic insulin mimetope.Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.Proinsulin is encoded by an RNA splice variant in human blood myeloid cells.Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvantRelative paradigms between autoantibodies in lupus and autoantibodies in cancer.Central and peripheral autoantigen presentation in immune tolerance.Etiopathogenesis of insulin autoimmunity.The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice.Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes.14th International HLA and Immunogenetics Workshop: report on the HLA component of type 1 diabetes.Non-antigenic and antigenic interventions in type 1 diabetesVaccination against self to prevent autoimmune disease: the type 1 diabetes model.Autoantibodies to tumor-associated antigens: reporters from the immune system.Viruses and cytotoxic T lymphocytes in type 1 diabetes.Antigen-based vaccination and prevention of type 1 diabetes.Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice.Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective.Genetic determinants of Type 1 diabetes: immune response genes
P2860
Q33321888-40C2E807-0249-46B7-B4AC-48A8C58DAA0DQ33937758-72B1E35B-48E5-4B97-A6A0-210B55BF65E7Q34234705-C09AF9A6-60A0-477E-B91A-436615E3FB7DQ34327132-D2C06C91-3642-4FEF-94EA-ED47A4B7F33FQ34583970-0E7022A3-C128-41C4-9DF7-3E5F24CAA803Q35102415-A4D16B92-E26B-4C56-9C4B-F262FF21E655Q35319290-B3940922-9244-4D0C-BF26-C3BD4D7B720BQ35583352-69CFD967-0197-4975-93A4-6CE50AC746AFQ35694446-1A31E756-CBB3-4D0D-AF22-C557743CAF92Q35910119-019C4A05-9345-4334-A864-4B657B9B942FQ36079920-BF95C4D4-0C66-458F-8FCD-F41D08E48ABDQ36755911-21D97CCE-54F3-4C1F-A1FB-45AC76A133ACQ36796008-671998D6-959D-4961-82EC-6F9358F409D1Q36977725-C8DF8CD0-2CF7-400C-AD36-EFD0E90ACAB7Q37052632-617E75F1-9AD5-43CE-8521-7966A88AFDF8Q37118192-1BD700E5-8DBD-45FD-8DE2-5D8B21291401Q37823420-2F98DA0E-0145-4403-B4A7-2D77DA22A8D0Q38124273-6DEFE22B-F15A-434B-AB1C-905041B3D0B9Q42739489-D45EF0E2-66B8-4BBE-9D79-0BA0FC94B0C9Q45886074-206E0DED-99FA-4FA2-9798-372B07DAE2E9Q47385058-C5C8BC04-4755-4243-8FCC-FE07BFE1933EQ56806352-2FB4FEAF-E15E-4729-8CCE-A5600F54F3E2
P2860
Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide
description
im Mai 2003 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2003
@uk
name
Disabling an integral CTL epit ...... intranasal proinsulin peptide
@en
Disabling an integral CTL epit ...... intranasal proinsulin peptide
@nl
type
label
Disabling an integral CTL epit ...... intranasal proinsulin peptide
@en
Disabling an integral CTL epit ...... intranasal proinsulin peptide
@nl
prefLabel
Disabling an integral CTL epit ...... intranasal proinsulin peptide
@en
Disabling an integral CTL epit ...... intranasal proinsulin peptide
@nl
P2093
P356
P1476
Disabling an integral CTL epit ...... intranasal proinsulin peptide
@en
P2093
Antonis K. Moustakas
David C. Jackson
Leonard C. Harrison
Luciano Adorini
Nathan R. Martinez
Petra Augstein
P304
P356
10.1172/JCI200317166
P407
P577
2003-05-01T00:00:00Z